The Combination Therapy of TACE and Ablation With Durvalumab in Hepatocellular Carcinoma at Intermediate Stage (TAD)

NCT04517227 · clinicaltrials.gov ↗

NA

Phase

UNKNOWN

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Hepatocellular Carcinoma

Interventions

DRUG: Durvalumab
PROCEDURE: Transcatheter Hepatic Arterial Chemoembolization (TACE)
PROCEDURE: Ablation

Sponsor

Fudan University